苏尔法萨拉诱导的爱斯坦-巴尔病毒阳性粘膜皮肤
Cedric Stabel1, F J Sherida H Woei-A-Jin2, Thomas Tousseyn3
1Department of Dermatology University Hospitals Leuven, Leuven, Belgium.
Case reports in hematology
|July 10, 2024
概括
爱斯坦-巴尔病毒 (EBV) 可以引起各种疾病,从轻微的感染到严重的淋巴增殖性疾病. 这一案例突出了EBV阳性粘膜皮肤,并表明硫沙拉是潜在的原因.
科学领域:
- 传染性疾病 传染性疾病
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 爱斯坦-巴尔病毒 (EBV) 具有广泛的临床谱,包括传染性单核病和淋巴增殖性疾病.
- 免疫受损的个体具有较高的EBV相关瘤的风险.
- 由EBV驱动的淋巴增殖性疾病包括一系列具有不同临床行为的疾病.
研究的目的:
- 报告一个艾普斯坦-巴尔病毒阳性粘膜皮肤的病例.
- 探索EBV阳性粘膜皮肤的潜在阳性原因.
- 研究免疫调节剂在EBV相关疾病中的作用.
主要方法:
- 病例报告详细说明了EBV阳性粘膜皮肤的临床表现,诊断结果和治疗方法.
- 对有关EBV相关淋巴增殖性疾病的相关文献的综述.
- 分析患者的药物 anamnesis,专注于免疫调节剂.
主要成果:
- 一名患有爱斯坦-巴尔病毒阳性粘膜皮肤的患者,是一种惰性淋巴增殖性疾病.
- 一种免疫调节药物sulfasalazine被确定为潜在的促成因素.
- 这一案例扩大了对EBV驱动条件及其潜在触发因素的理解.
结论:
- 阳性EBV粘膜皮肤是EBV相关的淋巴增殖性疾病的范围内的一个独特的临床实体.
- 苏尔法萨拉被认为是一种潜在的阳性原因,需要进一步调查.
- 了解药物诱导的EBV表现对于患者管理至关重要.
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
435
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
435
Drugs for Treatment of Ulcerative Colitis in IBD
134
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
134
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
365
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
365
Peptic Ulcer Disease I: Introduction
162
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
162
Peptic Ulcer Disease II: Pathophysiology
365
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
365


